Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)

NCT04574583 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

12

Enrollment

NIH

Sponsor class

Conditions

Metastatic Cancer
Solid Tumors

Interventions

DRUG: SX-682
DRUG: M7824
BIOLOGICAL: MVA-BN-CV301
BIOLOGICAL: recombinant fowlpox viral (FPV)-CV301

Sponsor

National Cancer Institute (NCI)